Recombinant human eythropoietin (rh-epo) is a well established treatment for many kinds of
anemia including the anemia of cancer with or without myelosuppressive chemotherapy …

The management of cancer-related anemia with erythropoietic agents presents many
unresolved issues. We reviewed the literature relating to epoetin alfa (Eprex®/Epypo®; …

A comment on this article appears in" Are erythropoietin receptors expressed in tumors?
Facts and fiction--more careful studies are needed." J Clin Oncol. 2007 May 1; 25 (13): 1813 …

Anaemia which develops as a consequence of malignancies is often treated using
recombinant human erythropoietin (rhEpo). Epo is now known as an anti-apoptotic factor for …

In this issue of Blood, Sinclair and colleagues and Swift and colleagues report that the Epo
receptor is barely detectable in nonhematopoietic tissues, casting doubt on the role of Epo …

Abstract Learning Objectives After completing this course, the reader will be able to: Relate
anemia to treatment outcome in a number of solid tumors. Relate hemoglobin level to quality …

Erythropoietin (Epo) regulates erythropoiesis by binding to its receptor (EpoR) and
promoting cell proliferation, differentiation and inhibition of apoptosis. Epo is widely used to …

Advanced cancer is frequently associated with a significant anemia that may be due to the
disease itself or the effect of concomitantly administered chemotherapeutic agents. In a …

Anemia is a frequent complication in cancer, occurring in more than 50% of patients with
malignancies. Several factors can cause anemia in these patients, such as blood loss …

Background and purpose: tumor-induced anemia often occurs in cancer patients, and is
corrected by recombinant human erythropoietins (rHuEPOs). Recent studies indicated that …